Format

Send to

Choose Destination
J Pharmacol Sci. 2015 Sep;129(1):72-7. doi: 10.1016/j.jphs.2015.08.003. Epub 2015 Aug 22.

Daily intake of β-cryptoxanthin prevents bone loss by preferential disturbance of osteoclastic activation in ovariectomized mice.

Author information

1
Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa, Japan.
2
Citrus Research Division, NARO Institute of Fruit Tree Science, National Agriculture and Food Research Organization, Shimizu, Shizuoka, Japan.
3
Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School of Natural Science and Technology, Kanazawa, Ishikawa, Japan. Electronic address: hinoi@p.kanazawa-u.ac.jp.

Abstract

Although β-cryptoxanthin, a xanthophyll carotenoid, has been shown to exert an anabolic effect on bone calcification, little attention has been paid thus far to the precise mechanism of bone remodeling. Daily oral administration of β-cryptoxanthin significantly inhibited osteoclastic activation as well as reduction of bone volume in ovariectomized mice. In vitro studies revealed that β-cryptoxanthin inhibited differentiation and maturation of osteoclasts by repression of the nuclear factor-κB-dependent transcriptional pathway. Our results suggest that supplementation with β-cryptoxanthin would be beneficial for prophylaxis and for therapy of metabolic bone diseases associated with abnormal osteoclast activation.

KEYWORDS:

Osteoblast; Osteoclast; Osteoporosis

PMID:
26342276
DOI:
10.1016/j.jphs.2015.08.003
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center